GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
C

CDT Equity CDT · USD

Health Care · US listing · 🇺🇸 United States

Compare

0.84

-35.87%

Close of 9 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About CDT Equity

From its filings with the US Securities and Exchange Commission

SEC filings

CDT Equity is based in Naples, Florida and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker CDT. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $39.2m. At that date it held total assets of $5.7m and shareholders' equity of −$7.2m.

Read the filing on SEC.gov ↗

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
3 Feb 2022
Head office
4851 TAMIAMI TRAIL NORTH, NAPLES, FL, 34103
Incorporated in
DE
Classification
Pharmaceutical Preparations
Filer status
<br>Emerging growth company

Leadership

Pay as last reported

  • Dr. Freda Lewis-HallIndependent Chairman of the Board$101,500
  • Dr. Andrew ReganChief Executive Officer, Director, since 2023$1.1m
  • Mr. James BlighChief Financial Officer, Senior Vice President, Director, since 2023$692,944
  • Ms. Chele FarleyIndependent Director$181,852
  • Mr. Simon FryIndependent Director$21,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Conduit Pharmaceuticals Inc focuses on disease agnostic life science solutions in San Diego.
  • AZD1656 addresses diabetes mellitus and Hashimoto’s Thyroiditis with clinical assets.
  • AZD5904 targets idiopathic male infertility and autoimmune diseases effectively.

Weaknesses

  • Conduit Pharmaceuticals Inc has limited clinical assets beyond AZD1656 and AZD5904.
  • The company relies on licensed clinical assets without mentioning internal R&D pipeline.
  • Conduit Pharmaceuticals Inc lacks a broad product portfolio in the Life Sciences Tools & Services sector.

Opportunities

  • Expanding AZD1656 to treat Graves’ disease and investigate side effects.
  • AZD5904’s potential to address idiopathic male infertility in the US market.
  • Growth in Life Sciences Tools & Services industry with new clinical assets.

Threats

  • Competition from other companies in the Life Sciences Tools & Services sector.
  • Regulatory challenges in developing clinical assets for autoimmune diseases.
  • Dependence on licensed assets without internal development capabilities.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.